Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

Critical Care Medicine

Volumn 29, Issue 11, 2001, Pages 2051-2059

  Bernard, Gordon R ^a,i   Ely, E Wesley ^a   Wright, Theressa J ^b   Fraiz, Joseph ^c   Stasek Jr, Jerome E ^d   Russell, James A ^e   Mayers, Irvin ^f   Rosenfeld, Brian A ^g   Morris, Peter E ^h   Yan, S Betty ^b   Helterbrand, Jeffery D ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ST VINCENT HOSPITAL   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ST PAUL S HOSPITAL   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activated protein C; Critical care; D dimer; Disseminated intravascular coagulopathy; Inflammation; Phase II clinical trial; Randomized controlled trial; Recombinant proteins; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; D DIMER; FIBRINOGEN; INTERLEUKIN 6; PLACEBO; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTE COUNT;

EID: 0035164538     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200111000-00003     Document Type: Article

References (59)

1. The mortality of hospital-acquired blood stream infections: Need for a new vital statistic?
2. Treating patients with severe sepsis
3. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
4. Increase in national hospital discharge survey rates for septicemia - United States
5. Age-specific incidence and outcome of sepsis in the US
6. Pathogenesis of disseminated intravascular coagulation in sepsis
7. Regulation and functions of the protein C anticoagulant pathway
8. Vascular-bed-specific hemostasis and hypercoagulable states
9. Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor
10. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium
11. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
12. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes
13. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide
14. The endothelial cell protein C receptor
15. Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway
16. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
17. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ or phorbol ester
18. Changes in the blood coagulation system associated with septicemia
19. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia
20. Review: Infectious diseases and coagulation disorders
21. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
22. Experimental endotoxin in humans: An analysis of cytokine release and coagulation, fibrinolytic and complement pathways
23. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon
24. Septic shock, multiple organ failure and disseminated intravascular coagulation: Compare patterns of antithrombin III, protein C and protein S deficiencies
25. Time course of hemostatic abnormalities in sepsis and its relation to outcome
26. Changes of the hemostatic network in critically ill patients - Is there a difference between sepsis, trauma, and neurosurgery patients?
27. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency
28. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
29. Evidence of activation of the protein C pathway during acute vascular damage induced by Mediterranean spotted fever
30. Activation of the host response in human Plasmodium faciparum Malaria: Relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels
31. Protein C in the treatment of coagulopathy in meningococcal disease
32. Treatment of purpura fulminans in meningococcemia with protein C concentrate
33. Use of protein C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans
34. Characterization and novel purification of recombinant human protein C from three mammalian cell lines
35. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
36. A trial of antioxidants N-acetylcysteine and procysteine in ARDS
37. The acute respiratory distress syndrome network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome
38. APACHE II: A severity of disease classification system
39. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α1-antitrypsin and α2-macroglobulin, in patients with disseminated intravascular coagulation
40. Direct detection of activated protein C in blood from human subjects
41. Activated protein C resistance and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation
42. The application of the principle of intention-to-treat to the analysis of clinical trials
43. Protein C (PC) levels in sepsis: Association with mortality
44. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications
45. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
46. Why immunomodulatory therapies have not worked in sepsis
47. CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
48. Endotoxin, sepsis, and the primrose path
49. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines
50. Molecular mechanisms of thrombosis in meningococcal septicaemia: The role of the protein C pathway in vivo
51. Regulation of thrombomodulin by tumor necrosis factor-alpha: Comparison of transcriptional and posttranslational mechanisms
52. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
53. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro
54. Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: Role of neutrophil elastase
55. Thrombomodulin: An overview and potential implications in vascular disorders
56. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
57. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men
58. Prevalence of the factor V Leiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor V Leiden detection
59. Effect of the factor V Leiden mutation on the severity of meningococcal disease